PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 24 No. 4
Pages: 1  2  3  
Previous
 

Why Do Psychiatrists Select or Switch an Antipsychotic?

By Lena Pyrkosch, Dipl Psych and Michael Linden, MD | April 1, 2007
Lena Pyrkosch is a research associate at the Rehabilitation Centre Seehof and Dr Linden is professor of psychiatry and psychosomatic medicine at the Charit University of Medicine in Berlin. Lena Pyrkosch has recieved research support from Janssen Pharma, Lilly Deutschland, and Sanofi Aventis. Dr Linden has collaborated on research projects with Janssen Pharmacy, Lilly Deutschlander, and Sanofi Aventis.

Is the present treatment working?
One view is that the physician's priority should be to help the patient overcome the illness. Others may decide that the priority must be to not harm the patient. This is a value decision. To help guide the physician's course of action, we must remember the rule: do everything possible to help the patient. When putting effectiveness first, the present illness status and, more important, the course of the current treatment has to be taken into account. If the current treatment has led to some progress, it should be continued unchanged.

Whatever the treatment strategy may have been—older or newer antipsychotics, low or high dosage, 1 drug or multiple medications—if it works, it is okay. No theoretical reason should make a physician change a successful treatment. If there is no convincing progress, the next step is to make sure that the medication is being taken as prescribed. One cannot argue that a drug did not work if it has not been used correctly. Double-check and correct dosages (ie, are they too high or too low), treatment duration, and patient adherence. If the present illness status has not improved in spite of an appropriate antipsychotic medication, do not wait, test something else and switch to another medication.

Is the current treatment tolerated?
Physicians should not harm patients (nil nocere). Negative drug effects have to be taken seriously and should be minimized as much as possible. Look for and ask about signs and symptoms of known adverse effects. Inquiring about adverse effects does not increase their prevalence, nor does it lead to nonadherence. Instead, the patient gets the feeling that the physician cares about his progress and well-being.

If there are adverse effects, the question is whether something can or must be done. Serious adverse effects that can cause severe harm (eg, tardive dyskinesia) must lead to a change in treatment, whether the patient likes the change or not. Subjective burdensome side effects should not be played down but should lead to a change in treatment whenever it is medically possible. Medical considerations should come first but don't forget to empathize with your patient.

Which drug should be selected next?
After the decision has been made that a change in medication is needed, the physician must decide which drug should be tried next. Factors listed in the RTSQ8 that should be considered include patient preferences, pharmacological profiles, drug interactions, potential side-effect profiles, costs, application modes, illness status, special drug effects, social and occupational status of the patient, recommendations by superiors, colleagues or others, and experience with the drug. Again, value judgments are necessary to determine what factors are most important. We think that in most cases the decision should start with consideration of the side effects.

This leads us to another rule:use rehabilitation pharmacotherapy and support participation. By and large, all antipsychotic medications are equally effective.30-33 However, there are relevant differences in respect to their side-effect profiles. Adverse effects are not only a medical problem, they also have consequences for participation in social or occupational life. For instance, sedation impairs working ability, impotence impairs connubial life, emotional flattening impairs social interaction, and weight gain impairs general health and self-confidence. All patients have special needs and individual problems. Rehabilitation pharmacotherapy,34 a new way of prescribing that aims to increase participation in social life in addition to (and perhaps even more than) reducing illness symptoms, takes all these factors into consideration.

Another important aspect is the patient's cooperation. Like most physicians, most patients have their own preconceived notions about certain drugs. They may also prefer different modes of application. The general rule should be to fulfill the patient's wishes whenever medically possible (treat your patient as if he were your client).

CONCLUSION
Pharmaceutical companies and scientists love to point to new developments, and it is their job to do so. They thus recommend new drugs more vigorously than older ones. They highlight their new pharmacological, side-effect, or efficacy profiles. They bring new literature to every physician desk and stimulate scientific debates on special aspects of new drugs. They even include these discussions in treatment guidelines.

Experienced physicians know that medical progress in antipsychotics has moved at a snail's pace and that many promises turn out to be empty or simply wishes and good intentions. Therefore, it is wise to stay with well-known drugs and not hop on the bandwagon of every new drug. It is also wise to use the same drug in most patients instead of using different drugs in each patient. Only by repeated prescribing is it possible to become thoroughly acquainted with a drug. Thus, it is wise to choose the drug that you have prescribed most often and with which you are most familiar.

Last but not least, physicians should be aware that they spend the money of other persons. Whenever possible they should help to reduce costs.

Pages: 1  2  3  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





  • Linden M, Pyrkosch L, Dittmann RW, Czekalla J. Why do physicians switch from one antipsychotic agent to another? J Clin Psychopharmacol. 2006;26:225-231.
  • Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol. 2006;20:815-823.

References
1. Jungermann H. Research on Decision Making in Clinical Contexts: Illustrations and Observations. Berlin: Technische Universität Berlin, Institut für Psychologie; 1992.
2. Jungermann H, Pfister HR, Fischer K. Die Psychologie der Entscheidung. Heidelberg, Berlin: Spektrum; 1998.
3. Linden M. The role of the patient in treatment decisions. In: Rush AJ, ed. Modern Problems of Pharmacopsychiatry. Basel, Switzerland: Karger; 1997:192-202.
4. Rush AJ. Modern Problems of Pharmacopsychiatry. Basel, Switzerland: Karger; 1997.
5. Schwartz JA, Chapman GB. Are more options always better? The attraction effect in physicians' decisions about medications. Med Decis Making. 1999;19:315-323.
6. Weinstein M, Fineberg H. Clinical Decision Analysis. Philadelphia: WB Saunders Company; 1980.
7. Dörner D, Kaminski G. Handeln-Problemlösen-Entscheiden. In: Immelmann K, Scherer KR, Vogel C, Schmoock P, eds. Psychobiologie: Grundlagen des Verhaltens. Stuttgart, Germany: Gustav Fischer; 1988:375-414.
8. Linden M. Begründungen von Ärzten für die Auswahl eines Arzneimittels: Der Therapiewahlfragebogen. Psychopharmakotherapie. 2004;11:76-79.
9. Patel VL, Kaufmann DR, Arocha JF. Emerging paradigms of cognition in medical decision-making. J Biomed Inform. 2002;35:52-75.
10. Schulte D, Vogel G. Der Prozess Therapeutischer Entscheidungen. In: Schulte D, ed. Therapeutische Entscheidungen. Göttingen: Hogrefe; 1991:151-179.
11. Langwieler G, Linden M. Therapist individuality in the diagnosis and treatment of depression. J Affect Disord. 1992;27:1-11.12. Bense A. Klinische Handlungstheorie. Weinheim, Germany: Beltz; 1981.
13. Kuhl J, Waldmann R. Handlungspsychologie: Vom Experimentieren mit Perspektiven zu Perspektiven fürs Experimentieren. Ztschr Sozialpsychol. 1985;16:153-181.
14. Linden M. Therapeutic standards in psychopharmacology and medical decision-making. Pharmacopsychiatry. 1994;27:41-45.
15. Linden M, Pyrkosch L, Dittmann RW, Czekalla J. Why do physicians switch from one antipsychotic agent to another? J Clin Psychopharmacol. 2006;26:225-231.
16. Linden M. Der Einfluss von Leitlinien, Standards und ökonomischen Vorgaben auf medizinische Entscheidungsprozesse. Z ärztl Fortbild Qual Gesundhwes. 2004;98:200-205.
17. Linden M, Baier D, Beitinger H, et al. Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. Pharmacopsychiatry. 1997;30:65-70.
18. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx. 2004;1:341-347.
19. Linden M. Controlled clinical trials and postmark- eting experience. Psychopharmakotherapie. 1997;6: 26-31.
20. Linden M, Scheel T, Eich FX. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. J Psychopharmacol. 2006;20:815-823.
21. Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol. In press.
22. Joukamaa M, Lehtinen V, Karlsson H. The ability of general practitioners to detect mental disorders in primary health care. Acta Psychiatr Scand. 1995;91:52-56.
23. Linden M. Theory and practice in the management of depressive disorders. Int Clin Psychopharmacol. 1999; 14:15-25.
24. Rush AJ, Prien RF. From scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged? Psychopharmacol Bull. 1995;31:7-20.
25. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
26. Linden M. Definition of compliance. Int J Clin Pharmacol Ther Toxicol. 1982;19:86-90.
27. Linden M. Phase-IV-Forschung. Antidepressiva in der Nervenarztpraxis. Berlin: Springer; 1987.
28. Stieglitz RD, Linden M. Compliance. In: Oldings-Kerber J, Leonhard JP, Hrsg. Pharmakopsychologie. Experimentelle und klinische Aspekte. Jena, Germany: Gustav Fischer Verlag; 1992:337-349.
29. National Collaborating Centre for Mental Health. Schizophrenia—Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Excellence (NICE); 2002.
30. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
31. Mortimer AM. How to choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol. 2004;7:21-25.
32. Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol. 2004;14:453-459.
33. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28:9-26.
34. Linden M, Müller W. Rehabilitations-Psychopharmakotherapie. Köln: Deutscher Ärzteverlag; 2006.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy